TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01889056
Drug: Erythropoietin (Epoetin beta)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02589717
Drug: Atezolizumab [TECENTRIQ]
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
Study: NCT04137185
Drug: Recombinant Human Thyroid Stimulating Hormone for Injection
Normalized name: Recombinant Human Thyroid Stimulating Hormone
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
Study: NCT00892177
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT02709525
Drug: hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01549054
Drug: 10-mg dose of E5501 2G tablet
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A: Single 10-mg dose of E5501 2G tablet
Study: NCT01549054
Drug: 10-mg dose of E5501 cyclodextrin oral solution
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
Study: NCT01549054
Drug: 10-mg dose of E5501 lipid-based oral
Normalized name: propofol lipid emulsion 10 MG/ML
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
Study: NCT00202566
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02624765
Drug: Digoxin (monotherapy)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
Study: NCT02624765
Drug: Sotalol (monotherapy)
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
Study: NCT02624765
Drug: Flecainide (monotherapy)
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose: 100 mg TID (300 mg/day)
Study: NCT03014102
Drug: Recombinant Human Thrombopoietin
Normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
Study: NCT00161447
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
Study: NCT00161447
Drug: Depo-Medroxyprogesterone
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMPA (injected into muscle) Day 0 \& month 3
Study: NCT02624765
Drug: Digoxin (dual therapy)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
Study: NCT02624765
Drug: Sotalol (dual therapy)
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose: 160 mg BID (320 mg/day)
Study: NCT01928901
Drug: administration of Sinupret
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01928901
Drug: administration of Bronchipret
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01819896
Drug: Pacemaker and defibrillator
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03910543
Drug: Tofacitinib 5 mg twice daily
Normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib will be administered at a dose of 5 mg twice daily
Study: NCT02624765
Drug: Flecainide (dual therapy)
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose:100 mg TID (300 mg/day)
Study: NCT00334347
Drug: Depakote ER
Normalized name: Depakote ER
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
Study: NCT00334347
Drug: Depakote DR
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
Study: NCT00005825
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005825
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005825
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03154996
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)
Study: NCT03154996
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
Study: NCT02289807
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
Study: NCT00999440
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
Study: NCT04442984
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Irinotecan 180mg/m² every two weeks
Study: NCT04442984
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study: NCT04442984
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1-2 5-FU 2200 mg/m² every two weeks
Study: NCT04442984
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 5-FU 250 mg/m² every two weeks
Study: NCT04442984
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 5-FU 400 mg/m² every two weeks
Study: NCT04442984
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1-2 5-FU 2400 mg/m² every two weeks
Study: NCT03837925
Drug: Atorvastatin 40mg Tablet
Normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient participation for 6 weeks of treatment
Study: NCT00318968
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03521323
Drug: Umbilical Cord Mesenchymal Stem Cells
Normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
Study: NCT01447914
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
Study: NCT03657290
Drug: vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vadadustat Tablets
Study: NCT01606384
Drug: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: oral
Study: NCT05967442
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
Study: NCT05967442
Drug: Metoclopramide 10mg
Normalized name: METOCLOPRAMIDE 10MG ORAL DISINTEGRAT TAB
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 10mg in 50ml D5W over 20 minutes
Study: NCT05967442
Drug: Prochlorperazine (Compazine) Injection
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine 10mg in 50ml D5W over 20 minutes
Study: NCT00697892
Drug: lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
Study: NCT02861898
Drug: Intra-arterial Cetuximab
Normalized name: methotrexate
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02861898
Drug: Intra-arterial Mannitol
Normalized name: methotrexate
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00697892
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
Study: NCT00697892
Drug: artemether/lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
Study: NCT00306683
Drug: DIAZOXIDE
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03480256
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
Study: NCT00489892
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01849094
Drug: Milrinone 6mg
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT01849094
Drug: milrinone 10mg ER
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT01849094
Drug: milrinone 14mg
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
Study: NCT02692755
Drug: Palbociclib + Letrozole or Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
Study: NCT00931229
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
Study: NCT04580797
Drug: PF-06700841 IR
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation
Study: NCT04580797
Drug: PF-06700841 MR1
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release formulation 1
Study: NCT04580797
Drug: PF-06700841 MR2
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release formulation 2
Study: NCT04580797
Drug: PF-06700841 MR3
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release formulation 3
Study: NCT02206035
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
Study: NCT02206035
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
Study: NCT00709618
Drug: Lapatinib, Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
Study: NCT01704846
Drug: BI 201335 NA 120 mg capsule
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1capsule of BI 201335 NA 120 mg capsule
Study: NCT01458418
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
Study: NCT01458418
Drug: 5 mg Montelukast
Normalized name: montelukast 5 MG
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
Study: NCT01704846
Drug: BI 201335 NA 120 mg capsule
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule of BI 201335 NA 120 mg capsule
Study: NCT01704846
Drug: BI 201335 NA 40 mg capsule
Normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules of BI 201335 NA 40 mg capsule
Study: NCT00323297
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
Study: NCT00323297
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
Study: NCT00323297
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
Study: NCT00751842
Drug: rhGAD65
Normalized name: rhGAD65
DrugBank: rhGAD65 (DB04963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
Study: NCT00751842
Drug: rhGAD65
Normalized name: rhGAD65
DrugBank: rhGAD65 (DB04963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
Study: NCT01271803
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Study: NCT01271803
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Study: NCT00530335
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
Study: NCT02966743
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of midazolam during spinal anesthesia for target bispectral index 75-80
Study: NCT02966743
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
Study: NCT05051137
Drug: Sulfasalazine + Hydroxychloroquine
Normalized name: Sulfasalazine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
Study: NCT03478163
Drug: CeFAZolin 1000 MG
Normalized name: cefazolin 1000 MG
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 1000 mg every 8 hours for 3 doses
Study: NCT00477854
Drug: Chromium Picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
Study: NCT01649791
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT04608669
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give paracetamol or placebo and compare temperature
Study: NCT00126022
Drug: Tedisamil sesquifumarate
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01581398
Drug: Ypeginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc, qw, 24 weeks.
Study: NCT01581398
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc, qw, 24 weeks.
Study: NCT03832660
Drug: Sacubitril/Valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
Study: NCT01971203
Drug: seroquel xr
Normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
Study: NCT01581398
Drug: Ypeginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc, qw, 48 weeks.
Study: NCT01581398
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc, qw, 48 weeks.
Study: NCT01335789
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IUs
Study: NCT01335789
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IUs
Study: NCT01394471
Drug: Intranasal Oxytocin Spray
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
Study: NCT01020448
Drug: Triptorelin (Decapeptyl®)
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
Study: NCT02934022
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
Study: NCT00567216
Drug: Nadolol
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study: NCT02580591
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03450109
Drug: Zoladex
Normalized name: Zoladex
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One Subcutaneous injection in the abdominal wall